ProPharma Group and The Planet Group announce unified brand and expanded capabilities. Learn more >

Initiating Enrollment for Accelerated COVID-19 Treatment Studies in 6 Days

In May 2020, as the FDA released new guidelines to accelerate the development of novel COVID-19 therapeutics and vaccines, our Clinical Services experts were asked to provide independent Data Safety Monitoring Board (DSMB) and Medical Monitoring resources for not just one, but two concurrent COVID-19 treatment studies scheduled to enroll Subjects in less than one week.

Find out how our dedicated project oversight paid off with two concurrent COVID-19 treatment studies initiated and ready for Subject enrollment in 6 days.

Download Case Study

Contact Us

Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.

We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.

Interested in gaining an industry edge? Let us help you stay up to date.

All fields are required.
There was a problem with your submission. Errors have been highlighted below.